Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

Interferon-alpha-2b (IFNalpha2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this a...

Full description

Bibliographic Details
Main Authors:	Hauschild, A, Gogas, H, Tarhini, A, Middleton, MR, Testori, A, Dréno, B, Kirkwood, J
Format:	Journal article
Language:	English
Published:	2008

Similar Items

A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
by: Ena Wang, et al.
Published: (2012-01-01)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
by: Kirkwood John M, et al.
Published: (2008-10-01)

A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.
by: Petr Pancoska, et al.
Published: (2014-01-01)

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
by: Fountzilas George, et al.
Published: (2010-11-01)

New challenges in endpoints for drug development in advanced melanoma.
by: Ribas, A, et al.
Published: (2012)

Systemic adjuvant therapy for high-risk cutaneous melanoma
by: Iyad Kobeissi, et al.
Published: (2022-10-01)

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
by: Hancock, B, et al.
Published: (2004)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
by: Alessandro A. E. Testori, et al.
Published: (2020-07-01)

Immunomodulating effect of adjuvant interferon inducers in patients receiving combined photocoagulation/ strontium-90 brachytherapy organ-saving treatment foruveal melanoma
by: L.N. Velychko, et al.
Published: (2015-07-01)

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
by: Islam Eljilany, et al.
Published: (2023-08-01)

Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts
by: Suzanne Fastner, et al.
Published: (2023-12-01)

Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
by: Middleton, M, et al.
Published: (2007)

Evaluation of interferon alpha 2b as adjunctive therapy for conjunctival melanoma
by: Matthew J. Benage, et al.
Published: (2019-09-01)

Aim high - Adjuvant interferon in melanoma (high risk): No confirmation yet that low dose interferon is of benefit
by: Hancock, B, et al.
Published: (2001)

Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials
by: Malczewski, A, et al.
Published: (2015)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
by: Konstantinos Christofyllakis, et al.
Published: (2021-02-01)

The effect of combined chemotherapy with or without potentiation with interferon alpha or tamoxifen for melanoma
by: Pejčić Ivica, et al.
Published: (2004-01-01)

French dermatologists' opinions and practices with regard to adjuvant therapy in stage III melanoma
by: Marion Rolland, et al.
Published: (2023-12-01)

Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma
by: Hemstock, M, et al.
Published: (2020)

Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients
by: Corina-Daniela Ene, et al.
Published: (2015-12-01)

Long-term pegylated interferon-&alpha; and its potential in the treatment of melanoma
by: Reinhard Dummer, et al.
Published: (2009-04-01)

CD56dim CD16− Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
by: Lazar Vujanovic, et al.
Published: (2019-01-01)

Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma
by: María Belén García-Ortega, et al.
Published: (2023-07-01)

Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence
by: Usha K Raina, et al.
Published: (2023-01-01)

Whole Body Cryostimulation: A New Adjuvant Treatment in Central Sensitization Syndromes? An Expert Opinion
by: Angelo Alito, et al.
Published: (2024-02-01)

Interferon alpha-induced reduction in the values of myeloid-derived suppressor cells in melanoma patients
by: Stanojević Ivan, et al.
Published: (2015-01-01)

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
by: Arjun Khunger, et al.
Published: (2021-01-01)

Patellofemoral arthroplasty: expert opinion
by: Paul Hoogervorst, et al.
Published: (2022-01-01)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
by: Mia Salans, et al.
Published: (2021-10-01)

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
by: Ahmad A Tarhini, et al.
Published: (2014-01-01)

Primary PEComa of the bladder treated with primary excision and adjuvant interferon-alpha immunotherapy: a case report
by: Wehrli Bret M, et al.
Published: (2006-08-01)

Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients
by: Kirkwood John M, et al.
Published: (2011-05-01)

IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.
by: Martin Probst, et al.
Published: (2014-01-01)

Verification of the expert’s opinion
by: M. H. Shcherbakovskyi, et al.
Published: (2022-09-01)

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients
by: Arjun Khunger, et al.
Published: (2019-11-01)

Adjuvant treatments in melanoma
by: Luka Simetić, et al.
Published: (2021-01-01)

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study
by: Francesca Urbani, et al.
Published: (2020-03-01)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
by: Dong-Dong Jia, et al.
Published: (2021-06-01)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
by: Wolfram Samlowski, et al.
Published: (2023-02-01)

Societal preferences for adjuvant melanoma health states: UK and Australia
by: Middleton, M, et al.
Published: (2017)